[{"id":"d2fe552c-f100-425e-934e-b8a426721a46","acronym":"IGNYTE","url":"https://clinicaltrials.gov/study/NCT03767348","created_at":"2021-01-18T18:38:28.476Z","updated_at":"2025-02-25T14:27:51.295Z","phase":"Phase 2","brief_title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab","source_id_and_acronym":"NCT03767348 - IGNYTE","lead_sponsor":"Replimune Inc.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-24"},{"id":"85b6b710-2ff1-4053-aee4-c2133e6bc508","acronym":"neoBREASTIM","url":"https://clinicaltrials.gov/study/NCT06067061","created_at":"2023-10-04T15:10:55.268Z","updated_at":"2024-07-02T16:34:59.994Z","phase":"Phase 1/2","brief_title":"\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer","source_id_and_acronym":"NCT06067061 - neoBREASTIM","lead_sponsor":"Institut Curie","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 04/05/2024","start_date":" 04/05/2024","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2031","study_completion_date":" 04/05/2031","last_update_posted":"2024-05-30"}]